Singapore-headquartered Zuellig Pharma, a leading healthcare solutions company in Asia, has expanded its commercialisation partnership with Karo Healthcare. Founded in 1987, Karo is a leading European consumer healthcare company headquartered in Stockholm, Sweden, with products available in more than 90 countries.

Under the new agreement, Zuellig Pharma will be the exclusive commercialisation partner for Karo's over-the-counter (OTC) brand Lamisil, a product for the treatment of fungal infections, across Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan and Vietnam.

With industry-leading coverage across healthcare professionals and retail pharmacies in Asia and in-market commercial expertise, ZP Therapeutics, the commercial division of Zuellig Pharma, will be steering this partnership.

Zuellig Pharma has had a strong commercialisation partnership with Karo since 2019 for its product portfolio in the Philippines, Vietnam, Singapore and Indonesia.